<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01034709</url>
  </required_header>
  <id_info>
    <org_study_id>C09-CMV-001</org_study_id>
    <nct_id>NCT01034709</nct_id>
  </id_info>
  <brief_title>Evaluation of the Artus® CMV PCR Test</brief_title>
  <acronym>CMV</acronym>
  <official_title>Clinical Evaluation of the Artus® CMV RG PCR Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QIAGEN Gaithersburg, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QIAGEN Gaithersburg, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with symptomatic CMV infection, who are enrolled in this clinical study, will be
      monitored during antiviral therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The human Cytomegalovirus (CMV) is found in blood, tissues and nearly all secretory fluids of
      infected persons. Transmission can be oral, sexual, via blood transfusion, organ
      transplantation, intrauterine, or perinatal. Infection with CMV preadolescence frequently
      leads to an asymptomatic infection followed by a lifelong persistence of the virus in the
      body. Infection post adolescence typically leads to symptoms that resemble those of
      mononucleosis (e.g., fever, fatigue, hepatitis, etc.) In contrast, CMV infections in immune
      compromised patients can be life threatening. A major cause of virus-associated morbidity and
      mortality in solid organ transplantation patients is illness caused by CMV (i.e., CMV
      syndrome or CMV disease).

      The risk of progressing to CMV disease post-transplant is strongly correlated with the
      serological status of the donor (D) and recipient (R); the highest risk group is R-/D+.
      Patients at risk for CMV disease can be managed either preemptively (i.e., patients are only
      treated with antiviral agents after evidence of CMV infection arises), or prophylactically
      (i.e., all patients are treated with antiviral agents regardless of CMV infection status).
      Monitoring of the CMV viral load of transplant patients during antiviral therapy provides an
      effective aid in the management of patients with CMV disease. The artus® CMV RG PCR test is a
      nucleic acid amplification-based assay for the quantitation of CMV DNA using PCR in the
      Rotor-Gene™ 6000 Instrument (also known as Rotor-Gene Q) with software version 2.0.2.3 or
      higher. In the present study the artus CMV RG PCR test result will be evaluated for its
      ability to safely and effectively monitor transplant patients during antiviral therapy and
      will be compared to the COBAS® AmpliPrep/COBAS® TaqMan® CMV Test
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>a) CMV Viral Load</measure>
    <time_frame>3 months</time_frame>
    <description>The CMV viral load was measured by both the artus CMV RG PCR test and the COBAS® AmpliPrep/COBAS® TaqMan® CMV Test at the investigational sites and then the percent agreement between the two tests was determined.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">111</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>Symptomatic</arm_group_label>
    <description>Subjects with a confirmed CMV viremia by the site's CMV-LDT as well as CMV symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic</arm_group_label>
    <description>Subjects who must have been serologically positive for CMV IgG prior to transplantation and do not have any CMV symptoms</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Extracted DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes subjects that have received a kidney transplant, and that are
        hospitalized or that present to a hospital, clinic or physicians office for
        post-transplantation care and will be treated with ganciclovir and/or valganciclovir for
        symptomatic CMV infection.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must have had a kidney transplant.

          2. Subjects that present at a hospital, clinic or physicians office for
             post-transplantation care.

          3. Subjects must be 18 years of age or older.

          4. Subjects providing informed consent.

          5. Subjects must have a CMV infection as demonstrated by a positive result by the site's
             CMV-PCR-Laboratory Developed Test (CMV-PCR-LDT)

          6. Subjects must be candidates for, and will be treated with ganciclovir and/or
             valganciclovir antiviral therapy.

        Exclusion Criteria:

          1. Subjects wherein the HIV status is positive.

          2. Specimens with less than 1.0 ml EDTA plasma for artus testing.

          3. Subjects from whom samples were collected, handled and/or stored inappropriately
             and/or determined to be unsatisfactory for processing/testing with the artus CMV RG
             PCR test (for which an explanation is provided in the case of subject exclusion).

             EDTA plasma specimens that have been stored inappropriately which include the
             following storage conditions: whole blood that has been frozen; whole blood processed
             for plasma more than 24 hours after collection; plasma stored at room temperature for
             more than 24 hours or 4C for more than 5 days at -20C for more than 6 months; frozen
             plasma with more than two freeze thaw cycles;

             Extracted nucleic acid that has been stored inappropriately which include the
             following storage conditions: extracted DNA stored for more than 5 days at -20C, or
             longer than six months at -20C; frozen nucleic acid with more than two freeze/thaw
             cycles.

          4. Specimens that have been stored inappropriately for testing with that test used by the
             site to demonstrate a CMV infection. (A site specific memo will be provided to QIAGEN
             on appropriate specimen storage conditions.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LifeLink Health Care Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://optn.transplant.hrsa.gov/</url>
    <description>Organ Procurement and Transplant Network</description>
  </link>
  <reference>
    <citation>Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997 Jan;10(1):86-124. Review.</citation>
    <PMID>8993860</PMID>
  </reference>
  <reference>
    <citation>Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006 Feb;6(2):262-74.</citation>
    <PMID>16426310</PMID>
  </reference>
  <reference>
    <citation>Greanya ED, Partovi N, Yoshida EM, Shapiro RJ, Levy RD, Sherlock CH, Stephens GM. The role of the cytomegalovirus antigenemia assay in the detection and prevention of cytomegalovirus syndrome and disease in solid organ transplant recipients: A review of the British Columbia experience. Can J Infect Dis Med Microbiol. 2005 Nov;16(6):335-41.</citation>
    <PMID>18159516</PMID>
  </reference>
  <reference>
    <citation>Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis. 1996 Mar;22(3):537-49. Review.</citation>
    <PMID>8852975</PMID>
  </reference>
  <reference>
    <citation>Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD; Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004 Apr;4(4):611-20.</citation>
    <PMID>15023154</PMID>
  </reference>
  <reference>
    <citation>Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis. 2000 Feb;181(2):717-20.</citation>
    <PMID>10669361</PMID>
  </reference>
  <reference>
    <citation>Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J Clin Virol. 2006 Apr;35(4):474-7. Epub 2006 Jan 6.</citation>
    <PMID>16406798</PMID>
  </reference>
  <reference>
    <citation>Hadaya K, Wunderli W, Deffernez C, Martin PY, Mentha G, Binet I, Perrin L, Kaiser L. Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay. J Clin Microbiol. 2003 Aug;41(8):3757-64.</citation>
    <PMID>12904387</PMID>
  </reference>
  <reference>
    <citation>Humar A, Gregson D, Caliendo AM, McGeer A, Malkan G, Krajden M, Corey P, Greig P, Walmsley S, Levy G, Mazzulli T. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation. 1999 Nov 15;68(9):1305-11.</citation>
    <PMID>10573068</PMID>
  </reference>
  <reference>
    <citation>Humar A, Siegal D, Moussa G, Kumar D. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis. 2005 Oct 1;192(7):1154-7. Epub 2005 Aug 23.</citation>
    <PMID>16136456</PMID>
  </reference>
  <reference>
    <citation>Piiparinen H, Helanterä I, Lappalainen M, Suni J, Koskinen P, Grönhagen-Riska C, Lautenschlager I. Quantitative PCR in the diagnosis of CMV infection and in the monitoring of viral load during the antiviral treatment in renal transplant patients. J Med Virol. 2005 Jul;76(3):367-72.</citation>
    <PMID>15902704</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>December 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2009</study_first_posted>
  <results_first_submitted>July 8, 2014</results_first_submitted>
  <results_first_submitted_qc>August 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2014</results_first_posted>
  <last_update_submitted>August 1, 2014</last_update_submitted>
  <last_update_submitted_qc>August 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytomegalovirus</keyword>
  <keyword>CMV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Symptomatic</title>
          <description>Subjects with a confirmed CMV viremia by the site's CMV-LDT</description>
        </group>
        <group group_id="P2">
          <title>Asymptomatic</title>
          <description>Subjects who are serologically negative for CMV IgG prior to transplantation and do not have any CMV symptoms</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Age, gender, and race/ethnicity data was not collected for the Asymptomatic arm of this study.</population>
      <group_list>
        <group group_id="B1">
          <title>Symptomatic</title>
          <description>Subjects with a confirmed CMV viremia by the site's CMV-LDT</description>
        </group>
        <group group_id="B2">
          <title>Asymptomatic</title>
          <description>Subjects who are serologically negative for CMV IgG</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="22" upper_limit="72"/>
                    <measurement group_id="B3" value="49" lower_limit="22" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American/ Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White/Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White/Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian/Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>a) CMV Viral Load</title>
        <description>The CMV viral load was measured by both the artus CMV RG PCR test and the COBAS® AmpliPrep/COBAS® TaqMan® CMV Test at the investigational sites and then the percent agreement between the two tests was determined.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symptomatic</title>
            <description>Subjects with a confirmed CMV viremia by the site's CMV-LDT</description>
          </group>
          <group group_id="O2">
            <title>Asymptomatic</title>
            <description>Subjects who are serologically negative for CMV IgG</description>
          </group>
        </group_list>
        <measure>
          <title>a) CMV Viral Load</title>
          <description>The CMV viral load was measured by both the artus CMV RG PCR test and the COBAS® AmpliPrep/COBAS® TaqMan® CMV Test at the investigational sites and then the percent agreement between the two tests was determined.</description>
          <units>percentage of agreement</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOQ IU/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.36"/>
                    <measurement group_id="O2" value="NA">No participants with detectable level in this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>500 IU/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.45"/>
                    <measurement group_id="O2" value="NA">No participants with detectable level in this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1000 IU/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.91"/>
                    <measurement group_id="O2" value="NA">No participants with detectable level in this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At time of blood collection.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Symptomatic</title>
          <description>Subjects with a confirmed CMV viremia by the site's CMV-LDT</description>
        </group>
        <group group_id="E2">
          <title>Asymptomatic</title>
          <description>Subjects who are serologically negative for CMV IgG</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kevin Modarress, PhD Senior Manager Regulatory Affairs Operations NA, Regulatory Affairs</name_or_title>
      <organization>QIAGEN</organization>
      <phone>301-944-7103</phone>
      <email>kevin.modarress@qiagen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

